Three Seed IP attorneys are scheduled to attend the 3rd Annual Summit on Life Sciences IP Due Diligence, presented by American Conference Institute (ACI), on November 14 and 15. This event is a one-of-a-kind, interactive forum where top diligence experts will discuss best practices and strategies for executing a proper IP due diligence analysis, both for your own portfolio, and that of potential targets.
The continued success of a life science company hinges upon successful partnerships. There are many corporate transactions involving life sciences IP that necessitate conducting due diligence. For example, you may be asked to engage your team members in the face of a merger or acquisition, an IPO, venture capital financing, in-licensing, partnering, co-development, or distribution agreements. How you structure your diligence is entirely dependent upon your objectives.
ACI’s 3rd Annual Summit on Life Sciences IP Due Diligence provides a forum for key industry stakeholders to master how to cultivate, navigate, and apply the results of an effective and profitable due diligence analysis.
Attending from Seed IP:
Eric A. Harwood, Ph.D. | Partner, Seed IP Law Group
Javier M. Mixco, M.D. | Associate, Seed IP Law Group
Eileen S. Sun, Ph.D. | Associate, Seed IP Law Group
Official website and agenda for the 3rd Annual Summit on Life Sciences IP Due Diligence - November 14 & 15, 2019